Yesterday, President Biden announced my appointment as a White House Fellow whitehouse.gov/briefing-room/… As the first oncologist ever selected, I'm excited to lead, serve, and innovate for our patients in this new role with the Cancer Moonshot and Health Outcomes teams White House Office of Science & Technology Policy

This career has given me the opportunity to meet the most beautiful, gifted world changers & the chance to see them when I travel. Arielle Elkrief, MD FRCPC, I am so blessed that our COVID-19 and Cancer Consortium (CCC19) Registry project gave me a lifelong 🇨🇦friend. Can’t wait to watch you go, do well, and do good. ❤️

Dr. Arielle Elkrief, MD FRCPC at the RESOT conference in Montreal showing potentially actionable MDM2 amplification particularly with a second driver present. Speaks to the potential value of NGS in later settings. Exciting work.

Post #RESOT conference, late night faculty trip to StViateurBagel for some Montreal bagels! A great end to a great meeting with Drs. Normand Blais, MD 🌻 Arielle Elkrief, MD FRCPC Jonathan Spicer MD PhD Frank Griesinger Nicolas Marcoux MD, FRCPC Jason Agulnik

Excited to share our study on the dysbiosis associated with #checkpointcolitis and ability to treat with #FMT. Fantastic collaboration with Arielle Elkrief, MD FRCPC and Jonathan (Tsoni) Peled who led the microbiome work. More to come in this space... Memorial Sloan Kettering Cancer Center pubmed.ncbi.nlm.nih.gov/38108398/?s=09

Happy to share our paper - FMT as an effective tx for refractory irColitis. We also characterized the fecal microbiome at symptom onset of irColitis and found enrichment of Proteobacteria such as E.Coli. Thanks to Jonathan (Tsoni) Peled David Faleck and of course the amazing Nick Waters

The Elkrief Lab is hiring Centre de recherche du CHUM! We are a translational lab focused on developing new biomarkers and therapies for patients with #lungcancer and #melanoma. Looking for #ComputationalBiologist, #Postdocs, and Research Assistants to join us in #MTL . icm.qc.ca/author/arielle…

New job opportunity - joint position in Bertrand Routy MD,PhD and Elkrief lab answering key questions in microbiome clinical trials (FMT, prebiotics, diet, probiotics...) in Montreal.

Among PDL1 high NSCLC, PFS and OS better with PDL1 ≥90% compared to 50-89%, report JTO & JTO CRR. Seen with 1L pembrolizumab (PFS HR 0.69, OS HR 0.70) and cemiplimab in EMPOWER-Lung 1 (PFS HR 0.53, OS HR 0.63). PDL1 50-80% enriched for STK11 and SMARCA4 mt jtocrr.org/article/S2666-…

This groundbreaking investment signifies a bold leap forward in understanding the intricate interplay between the human microbiome and cancer progression (3/3) #Cancer #MelanomaAwarenessMonth #Microbiome #CancerResearch

Great new read from Arielle Elkrief, MD FRCPC and co-authors: a timely analysis in npj Journals #PrecisionOncology showing that #antibiotics prior to chemo-immunotherapy is strongly associated with worse outcomes for lung #cancer patients. nature.com/articles/s4169…

Thank you to Society for Immunotherapy of Cancer and Melanoma Research for supporting our research!

Gut microbiome and immunotherapy Antibiotics 🔽 immunotherapy efficacy: use judiciously Approaches to dysbiosis 👉 Faecal microbial transplant 👉 Dietary change 👉 Probiotics 👉 Eliminate antibiotics Great talk from Arielle Elkrief, MD FRCPC #WCLC24 #LCSM

Lear More about Challenges & Controversies in Immunotherapy from Clarissa Baldotto, Misako Nagasaka, Anil Tibdewal, Arielle Elkrief, MD FRCPC, David Gandara & ProfSiowMingLee, who are currently presenting at #WCLC24. #LCSM #IASLC50 #LungCancer

Combination targeted therapies of independent but cooperating pathways, an understudied therapeutic strategy for prolonged disease control (cures?) ascopubs.org/doi/10.1200/PO… Arielle Elkrief, MD FRCPC Igor Odintsov Gʀᴇɢᴏʀʏ Rɪᴇʟʏ Robert C. Doebele, MD, PhD #LCSM #LCSM Chat Basse Clémence EGFR Resisters RETpositive